The effects of nanomicelle of curcumin on the matrix metalloproteinase (MMP-۲, ۹) activity and expression in patients with coronary artery disease (CAD): A randomized controlled clinical trial

  • سال انتشار: 1399
  • محل انتشار: مجله آریا آترواسکلروز، دوره: 16، شماره: 3
  • کد COI اختصاصی: JR_RYA-16-3_005
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 231
دانلود فایل این مقاله

نویسندگان

Marzieh Mogharrabi

Associate Professor, Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Hamid Reza Rahimi

Assistant Professor, Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Shima Hasanzadeh

Associate Professor, Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Mostafa Dastani

Associate Professor, Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Reza Kazemi-Oskuee

Associate Professor, Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Saeed Akhlaghi

Assistant Professor, Psychiatry and Behavioral Sciences Research Center AND Department of Psychiatry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Mohammad Soukhtanloo

Associate Professor, Pharmacological Research Center of Medicinal Plants AND Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

چکیده

BACKGROUND: Coronary artery disease (CAD) is the most common type of cardiovascular disease. Increasing the expression and activity of matrix metalloproteinases (MMPs) facilitates vascular remodeling and cardiovascular complications. Curcumin (the active ingredient of turmeric) is a potent natural anti-inflammatory agent, with cardiovascular protective effects. The present study was a clinical trial for investigating the effects of curcumin on activity and gene expression of MMP-۲ and MMP-۹ in patients with CAD.METHODS: In this study, ۷۰ patients with CAD (with ۴۰%-۵۰% stenosis) were randomly divided into two groups of curcumin (۸۰ mg nanomicelle per day) and placebo. The intervention lasted ۳ months. The activity levels of MMP-۲ and MMP-۹ in serum samples of patients were measured using gelatin zymography assay before and after the intervention. MMP-۲ and MMP-۹ gene expression in peripheral blood mononuclear cells (PBMCs) was also analyzed using real-time polymerase chain reaction (PCR). Statistical significance was set at P < ۰.۰۵۰۰.RESULTS: After ۳ months of medication, the expression of MMP-۹ produced by PBMCs significantly decreased in the curcumin group (۰.۸۱۱ ± ۰.۲۵) in comparison with the placebo group (۲.۲۳ ± ۰.۹۴) (P < ۰.۰۰۰۱). Furthermore, the zymographic analysis showed that the administration of curcumin significantly inhibited the activity levels of MMP-۲ (۱۲۴۶۹.۷ ± ۵۳۰۸.۶۴ pixels) and MMP-۹ (۱۴۰۰۷.۲ ± ۵۳۷۱.۶۷ pixels) in comparison with that in patients receiving placebo (MMP-۲: ۱۷۶۱۳.۸ ± ۵۲۵۰.۶۸ pixels; MMP-۹: ۲۰۰۱۰.۱ ± ۳۲۵۹.۳۷ pixels) (P < ۰.۰۵۰۰).CONCLUSION: Our results show that curcumin can significantly reduce the expression and activity of MMP-۲ and MMP-۹. Because of the anti-inflammatory effects of curcumin, this compound can be considered as a new strategy for the prevention of cardiovascular events.

کلیدواژه ها

Curcumin, Matrix Metalloproteinases, Coronary Artery Disease

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.